Phapros Extraordinary General Meeting Approves Changes to Board of Commissioners and Directors
Jakarta (ANTARA) - The extraordinary general meeting of shareholders (EGM) of PT Phapros Tbk (PEHA) has approved the reappointment and changes to the composition of the board of commissioners and board of directors.
Phapros Corporate Secretary Zahmilia Akbar stated in Jakarta on Thursday that the EGM approved the honourable dismissal of President Commissioner for the 2021-2026 period, Maxi Rein Rondonuwu, Independent Commissioner for the 2021-2026 period, Chrisma Aryani Albandjar, and Director of Finance, Risk Management & Human Resources for the 2023-2026 period, Yudhi Rangkuti.
Subsequently, the EGM of the subsidiary of state-owned enterprise PT Kimia Farma (Persero) Tbk, held in Jakarta on Monday (27/4/2026), approved the appointment of President Commissioner Alfi N Rustam, Independent Commissioner Nurjayanto Kusumawardhono, President Director Intan Abdams Katoppo, and Director of Finance, Risk Management & Human Resources Ferdinand Troedu.
As the new helm of PEHA, Intan has extensive experience in leading corporations, both private companies and state-owned enterprises.
The following is the management structure of Phapros in accordance with the 2026 EGM decision.
Board of Commissioners:
President Commissioner: Alfi Novtriansyah Rustam
Independent Commissioner: Nurjayanto Kusumawardhono
Independent Commissioner: Bimo Wijayanto
Commissioner: Masrizal Achmad Syarief
Board of Directors:
President Director: Intan Abdams Katoppo
Director of Production: Ida Rahmi Kurniasih
Director of Marketing: Maraja Jeson Siregar
Director of Finance, Risk Management & Human Resources: Ferdinand Troedu
Zahmilia expressed thanks to the previous board of commissioners and directors, noting that the company has navigated a challenging period over the past five years and demonstrated growth in its financial performance in 2025.
According to her, the changes to the board of commissioners and directors represent a form of refreshment, and she hopes the company can continue the business transformation that has been initiated to achieve sustainable performance growth in the coming years.
“Phapros remains committed to providing the best health products and services to the Indonesian people while aiming for positive growth as a professional and healthy corporation, because maintaining the trust of all stakeholders is our primary goal,” Zahmilia stated.